- Investors accused Walgreens execs of misleading them on deal
- Accord reached as jury trial loomed in securities-fraud case
Deerfield, Illinois-based Walgreens – the second-largest US pharmacy chain – will pay Rite Aid shareholders to settle a federal class-action lawsuit accusing the company of making false statements about how likely it was regulators would approve the deal, according to a court filing published late Tuesday.
Those statements artificially inflated Rite Aid’s stock price and when the merger
“Settlement negotiations were difficult, adversarial, and vigorously executed by both sides,” the investors’ lawyers said in the court document.
The accord was reached three weeks before the federal securities-fraud case was set to go to trial before US District Judge Christopher Conner. In April, the judge told Walgreens’ lawyers in a pre-trial hearing they should consider settling.
Walgreens officials didn’t immediately respond to an email seeking comment on Wednesday.
The settlement should provide some much-welcome news for investors in Rite Aid, which filed for
Eight years ago, Rite Aid executives agreed to a $17.2 billion buyout bid by Walgreens to acquire the chain’s more than 4,000 stores. But the bid – which had gone through several alterations — fell apart in 2017 because of antitrust concerns. Walgreens wound up paying
Chabot v. Walgreens Boots Alliance, Inc. 18-cv-02118, US District Court for the Middle District of Pennsylvania (Harrisburg).
To contact the reporter on this story:
To contact the editors responsible for this story:
Jeremy Hodges
© 2023 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.